Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H19N5O2S.ClH |
Molecular Weight | 393.891 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CNC1=NN2C(N=CC3=C2CCN(C)C3)=C1S(=O)(=O)C4=CC=CC=C4
InChI
InChIKey=HLQZXWFRTGIZIJ-UHFFFAOYSA-N
InChI=1S/C17H19N5O2S.ClH/c1-18-16-15(25(23,24)13-6-4-3-5-7-13)17-19-10-12-11-21(2)9-8-14(12)22(17)20-16;/h3-7,10H,8-9,11H2,1-2H3,(H,18,20);1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C17H19N5O2S |
Molecular Weight | 357.43 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:36:23 GMT 2023
by
admin
on
Sat Dec 16 10:36:23 GMT 2023
|
Record UNII |
B7DM6S48B2
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
135905417
Created by
admin on Sat Dec 16 10:36:23 GMT 2023 , Edited by admin on Sat Dec 16 10:36:23 GMT 2023
|
PRIMARY | |||
|
1194574-68-9
Created by
admin on Sat Dec 16 10:36:23 GMT 2023 , Edited by admin on Sat Dec 16 10:36:23 GMT 2023
|
PRIMARY | |||
|
B7DM6S48B2
Created by
admin on Sat Dec 16 10:36:23 GMT 2023 , Edited by admin on Sat Dec 16 10:36:23 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: ChemDiv; Developer: AllaChem, Avineuro Pharmaceuticals; Class: Nootropic, Pyrimidine, Small molecule; Mechanism of Action: Serotonin 6 receptor antagonist; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phase: Phase I for Alzheimer's disease; Most Recent Events: 13 Nov 2013 Phase-I development is ongoing in USA, 13 Nov 2013 AVN 322 sublicensed to AllaChem before Nov 2013, 16 Jun 2009 Phase-I clinical trials in Alzheimer's disease in USA (unspecified route)
|
||
|
ACTIVE MOIETY |
Company: Avineuro Pharmaceuticals Inc.; Description: Serotonin (5-HT6) receptor antagonist; Molecular Target: Serotonin (5-HT6) receptor; Mechanism of Action: Serotonin (5-HT6) receptor antagonist; Therapeutic Modality: Small molecule; Latest Stage of Development: Phase I; Standard Indication: Alzheimer's disease (AD); Indication Details: Treat Alzheimer's disease (AD); Partner: AllaChem LLC
|